samedan logo
 
 
spacer
home > ict > winter 2018 > protected and prepared
PUBLICATIONS
International Clinical Trials

Protected and Prepared

The European clinical research industry is in a period of great uncertainty. As it reckons with current trends – such as a decline in favourability as a clinical trial destination in favour of the Asia Pacific (APAC) region and other geographies – it is simultaneously bracing itself for other changes on the horizon. These upcoming changes are largely regulatory in nature; new regulations are related to advanced therapy medicinal products (ATMPs) and medical devices, which could both add and relieve headaches for researchers (1). Also, the new Clinical Trial Regulation is coming in 2019. Furthermore, after Brexit takes effect that same year, the UK may exempt itself from the Regulation, possibly creating complexities and uncertainties both there and in the post-Brexit EU (2).

Then there is the Greater Data Protection Regulation (GDPR): a vast set of rules and guidelines aimed largely at securing the personal data of EU citizens stored and processed online. While designed for the protection of Europeans, the effects of the GDPR are by no means limited to Europe: EU nationals anywhere in the world are protected by the new law – the personal data of a German citizen living and working in Australia, for example, would be covered – lending it significance on a global level. Given its breadth and its imminence (the law is set to take effect in May of this year), it behooves one to examine the context from which it emerged, as well as how the clinical research industry falls within its scope. Indeed, clinical research and the healthcare industry, at large – which stores massive quantities of personal data in formats such as electronic medical records and clinical trial databases – is bracing for the impact of the GDPR on its operations. What events set the stage for the GDPR, how will it affect Europe’s status as a clinical trial destination, and how can organisations ensure compliance?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mike Novotny is the founder and CEO of Medrio – a provider of cloud-based electronic data capture, eSource, and ePRO tools for clinical trials. Mike applies 20 years of experience in research and software to his eClinical Software-as-a-Service vision.

Nick O’Brien leads content marketing efforts at Medrio. At the company, he spearheads co-marketing initiatives, such as complimentary case studies with customers, and creates and commissions content for marketing campaigns. He brings years of experience in copywriting and blogging to his role and holds a BA from Kenyon College, US.

spacer
Mike Novotny
spacer
spacer
spacer
Nick O’Brien
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

rfxcel Covers the Cost of EMVO Onboarding Fees

May 23, 2018 - San Ramon, CA – rfxcel Corporation, a technically certified Gateway Provider for the European Medicines Verification Organisation (EMVO) announced today that it will pay the cost of statutory fees payable to EMVO* for all manufacturers (Marketing Authorisation Holders, MAHs) which select rfxcel as their Gateway Provider before June 15th 2018.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

ACHEMA 2018

11-15 June 2018, Messe Frankfurt GmbH

ACHEMA is the world forum for the process industries, but also an integral part of the trade show calendar of companies specializing in pharma packaging. Every three years 3,800 exhibitors and 170,000 visitors gather in Frankfurt/Main, Germany for the trade show that features everything you need to furnish a chemical or pharma production plant.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement